Toutes les études
Actif, mais pas en recrutementPHASE3INTERVENTIONNEL

Long Term Extension Study in Patients With Primary Hyperoxaluria

This study is for people who have already taken part in earlier research for a medicine called DCR-PHXC, which treats a rare kidney condition called Primary Hyperoxaluria (PH). It also welcomes their siblings under 18 years old who have PH. The main goal is to let these patients continue getting DCR-PHXC for a longer time. Researchers will closely watch to see if the medicine is safe and if it continues to work well in managing PH. This helps gather more information about the long-term effects of DCR-PHXC, which is important for understanding how best to treat this serious genetic condition affecting the kidneys.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE3
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Objectif d'inscription
75
Démarrer
09 Jul 2019
Achèvement estimé
01 Apr 2030

De quoi parle cette étude ?

This study is looking at a medicine called DCR-PHXC, which is designed to help people with a rare genetic condition called Primary Hyperoxaluria (PH). PH causes too much of a substance called oxalate to build up in the body, which can severely damage the kidneys and other organs. There are different types of PH, including PH1, PH2, and PH3.

This particular study is a 'long-term extension study.' This means it's for people who have already been part of earlier studies looking into DCR-PHXC. It gives them the chance to keep receiving the treatment. It's also open to younger brothers or sisters (under 18) who have PH. The main purpose is to find out if DCR-PHXC is safe and effective when used over a longer period.

By gathering more information over time, doctors and researchers can better understand how this new treatment works and whether it can safely help patients manage their PH in the long run. This is crucial for developing better treatment options for this challenging kidney disease.

Points clés

  • This study is for long-term treatment of Primary Hyperoxaluria (PH).
  • It's open to previous study participants and their younger siblings with PH.
  • The medicine being studied is called DCR-PHXC.
  • Researchers will check how safe and effective the medicine is over time.
  • Good kidney function is generally required to join.
  • You cannot join if you are on dialysis or have had an organ transplant.

Qui peut être éligible ?

This study is mainly for people who have already successfully taken part in a previous study of DCR-PHXC. If you've been in one of those studies, you might be able to join this one.

Also, brothers or sisters under the age of 18 who have been diagnosed with PH through a genetic test may be able to join if their sibling was in a previous DCR-PHXC study.

There are a few health requirements, including having reasonably good kidney function (your doctor can check this). You can't join if you've had a kidney or liver transplant, are currently on dialysis, or have signs that oxalate has severely affected other parts of your body.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Have you previously taken part in a DCR-PHXC study and completed it?
  2. If not, do you have a brother or sister who completed a DCR-PHXC study, and are you under 18 with genetically confirmed PH?
  3. Do you have reasonably good kidney function (your doctor can check this)?
  4. Have you not had a kidney or liver transplant?
  5. Are you not currently receiving dialysis treatment?
  6. Do you not have signs of widespread oxalate damage in your body?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will continue to receive the study medicine, DCR-PHXC. The exact schedule for taking the medicine and for your clinic visits will be explained by the study team. You will have regular appointments where doctors will check your general health, kidney function, and the levels of certain substances in your blood and urine to see how the medicine is working and if it's safe for you. These checks will involve blood tests and urine samples, and possibly other tests as needed. The study aims to follow participants for a longer period, so you'll have ongoing monitoring and follow-up care.

Risques et avantages potentiels

Taking part in this study may offer the benefit of continuing to receive a promising treatment for your Primary Hyperoxaluria. Your health will be closely monitored, which could help manage your condition. However, like all medicines, DCR-PHXC may have side effects, and some tests might be uncomfortable. The study team will explain all known or potential risks to you. Remember, joining is completely voluntary, and you have the right to leave the study at any time without affecting your medical care.

Locations (23)

  • Clinical Research Site
    Code postal vérifié
    San Francisco, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Boston, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    Rochester, États-Unis
  • Clinical Trial Site
    Code postal vérifié
    New York, États-Unis
  • Clinical Research Site
    Code postal vérifié
    Herston, Australia
  • Clinical Trial Site
    Code postal vérifié
    Melbourne, Australie
  • Clinical Research Site
    Code postal vérifié
    Hamilton, Canada
  • Clinical Trial Site
    Code postal vérifié
    Bron, France
  • Clinical Trial Site
    Code postal vérifié
    Paris, France
  • Clinical Trial Site
    Code postal vérifié
    Bonn, Germany
  • Clinical Trial Site
    Code postal vérifié
    Heidelberg, Allemagne
  • Clinical Research Site
    Code postal vérifié
    Roma, Italy

Questions fréquentes

What is Primary Hyperoxaluria?

It's a rare genetic condition where the body makes too much of a substance called oxalate, which can build up and damage the kidneys and other organs.

What is DCR-PHXC?

It's the name of the new medicine being studied to help treat Primary Hyperoxaluria.

Qui peut participer à cette étude ?

Mostly people who've already been in DCR-PHXC studies, or their siblings under 18 with a confirmed diagnosis of PH.

Devrai-je payer pour participer à l'étude ?

No, all study-related medical care and the study medicine will be provided without charge.

Combien de temps l'étude durera-t-elle pour moi ?

The study is for long-term treatment, so you will continue to receive the medicine and be monitored as long as it's safe and beneficial, and you wish to continue.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.